You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Coprescribing azathiopurine or 6mercaptopurine and 5aminosalicylate compounds in ulcerative colitis

Mayberry, H.1; Moshkovska, T. MD1; Mayberry, J. F. MD1*

Inflammatory Bowel Diseases:
doi: 10.1002/ibd.20750
Original Article

Background:: A total of 254 senior consultant gastroenterologists with valid e‐mail addresses were identified from the membership list of the British Society of Gastroenterology (BSG) 2007.

Methods:: They were sent by e‐mail a questionnaire which dealt with aspects of clinical practice and addressed cancer prevention in ulcerative colitis (UC). Replies were received from 97 clinicians (38% response rate).

Results:: Ninety‐one (94%) advised patients with established UC to take 5‐aminosalicylate (5‐ASA) compounds for life. Seventy‐two of the 91 (79%) clinicians co‐prescribed 5‐ASA compounds with immune modulators for patients with UC. Only 3 clinicians advised patients to take folic acid as a daily supplement. A median of 20% (interquartile range 10%–50%) of their patients with UC were co‐prescribed a 5‐ASA compound and azathioprine or 6‐mercaptopurine. Of these, a median of 3.5% (interquartile 1%–5%) developed neutropenia.

Conclustions:: Future research needs to be directed at the long‐term maintenance treatment and to address questions about which drugs should be used, in what combinations, and with what frequencies.

Author Information

1 Department of Digestive Diseases, Leicester General Hospital, Leicester, United Kingdom

* Department of Digestive Diseases, Leicester General Hospital, Gwendolen Road, Leicester LE5 4PW, UK


Received 22 July 2008; Accepted 5 August 2008

Published online 6 October 2008 in Wiley InterScience (

© Crohn's & Colitis Foundation of America, Inc.

You currently do not have access to this article.

You may need to:

Note: If your society membership provides for full-access to this article, you may need to login on your society’s web site first.